Resistin-like molecule-beta inhibits SGLT-1 activity and enhances GLUT2-dependent jejunal glucose transport.: RELM-beta increases glucose absorption by Belharbi Krimi, Rim et al.
Resistin-like molecule-beta inhibits SGLT-1 activity and
enhances GLUT2-dependent jejunal glucose transport.
Rim Belharbi Krimi, Philippe Lette´ron, Pia Chedid, Corinne Nazaret, Robert
Ducroc, Jean-Claude Marie
To cite this version:
Rim Belharbi Krimi, Philippe Lette´ron, Pia Chedid, Corinne Nazaret, Robert Ducroc, et al..
Resistin-like molecule-beta inhibits SGLT-1 activity and enhances GLUT2-dependent jejunal
glucose transport.: RELM-beta increases glucose absorption. Diabetes, American Diabetes
Association, 2009, 58 (9), pp.2032-8. <10.2337/db08-1786>. <inserm-00401901>
HAL Id: inserm-00401901
http://www.hal.inserm.fr/inserm-00401901
Submitted on 6 Jul 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
 
 
 
Resistin-like molecule- inhibits SGLT-1 activity and enhances GLUT2-dependent 
jejunal glucose transport 
 
Running title: RELM- increases glucose absorption  
 
Rim Belharbi Krimi, PhD, Philippe Letteron, PhD,  Pia Chedid, Corinne Nazaret, Robert 
Ducroc, PhD, and Jean-Claude Marie, PhD. 
INSERM, U773, Centre de Recherche Biomédicale Bichat 
Beaujon CRB3, Paris, France, Université Paris 7 Denis Diderot, Site Bichat, 
Paris, France. 
Supported by grants from INSERM and Nestlé. 
Reprints: Jean-Claude Marie, INSERM U773, Centre de Recherche Biomédicale Bichat 
Beaujon CRB3, BP 416, F-75018, Paris, France  
Tel : 00 33 01 5 7 2 7 74 82 
Fax : 00 33 01 5 7 2 7 74 71 
e-mail: jean-claude.marie@inserm.fr 
 
 
 
 
 2 
 
ABSTRACT 
OBJECTIVE: An increased expression of RELM- (Resistin-Like Molecule-), a gut-
derived hormone, is observed in animal models of insulin resistance/obesity and intestinal 
inflammation. Intestinal sugar absorption is modulated by dietary environment and 
hormones/cytokines. The aim of this study was to investigate the effect of RELM- on 
intestinal glucose absorption. RESEARCH DESIGN AND METHODS: Oral glucose 
tolerance test (OGTT) was performed in mice and rats in the presence and the absence of 
RELM- The RELM- action on glucose transport in rat jejunal sacs, everted rings and 
mucosal strips was explored as well as downstream kinases modulating SGLT-1 and 
GLUT2 glucose transporters. RESULTS: OGTT carried out in rodents showed that oral 
administration of RELM- increased glycemia. Studies in rat jejunal tissue indicated that 
mucosal RELM- promoted absorption of glucose from the gut lumen. RELM- had no 
effect on paracellular mannitol transport suggesting a transporter-mediated transcellular 
mechanism. In studies with jejunal mucosa mounted in Ussing chamber, luminal RELM- 
inhibited SGLT-1 activity in line with a diminished SGLT-1 abundance in brush border 
membranes (BBMs). Further, the potentiating effect of RELM- on jejunal glucose uptake 
was associated with an increased abundance of GLUT2 at BBMs. The effects of RELM-  
were associated with an increased amount of PKC II in BBMs and an increased 
phosphorylation of AMPK. CONCLUSIONS: The regulation of SGLT-1 and GLUT2 by 
RELM-expands the role of gut hormones in short-term AMPK/PKC mediated control of 
energy balance. 
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The family of proteins called « RELMs » for resistin-like molecules has been 
reported to be involved with insulin resistance, diabetes and inflammatory processes. 
Resistin was initially identified as an adipokine which inhibits insulin action and adipocyte 
differentiation (1). RELM-β is a protein homologous to resistin which is localized mainly 
within the digestive tract (2,3). RELM-β is highly expressed in goblet cells of murine colon 
and is secreted in response to bacterial colonisation. It plays an important role in host 
defense and innate immunity (4,5).  We have also shown that RELM-β may have a direct 
effect on intestinal goblet cell secretion (6) and others have shown that RELM-β can also act 
as a hormone.  An acute perfusion of RELM-β in rat induced a hepatic insulin resistance (7).  
  Recently, a concomitant  increase of serum concentration and intestinal expression of 
RELM-β has been reported in insulin-resistant models such as obese db/db mice and high-fat-
fed mice (8). Interestingly, the intestinal expression of RELM-β in mice is controlled by 
fasting and also by various nutritive elements such as glucose and saturated free fatty-acids 
(9). Glucose reduces the enterocyte expression of RELM-β while insulin and TNF can 
upregulate its expression (9). This suggests that intestinal RELM-β may not only be 
associated with inflammation but can also be a regulator of energy homeostasis. 
 Glucose, the main source of energy in humans, comes from the digestion of 
carbohydrates and is absorbed in the small intestine. Intestinal sugar absorption constantly 
adapts to the dietary environment (10). One risk factor for developing non-insulin-dependent 
diabetes (NIDDM) is the excessive consumption of diets containing high levels of 
carbohydrates. An important defect in NIDDM is the increased ability of intestine to absorb 
monosaccharides by intestinal sugar transporters (11). Intestinal glucose is actively 
transported by the Na
+
/glucose cotransporter-1 (SGLT-1) and passively by glucose 
transporter2 (GLUT2), (10). Moreover, it is also becoming increasingly evident that the gut is 
not just site of nutrient absorption but is also an active endocrine organ (12,13). A paracrine 
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regulation of hexose absorption by intestinal hormones such as glucose-dependent 
insulinotropic polypeptide (GIP) and proglucagon-derived peptides GLP-1 and GLP-2 has 
been shown (10). Indeed, certain gastro-intestinal peptides secreted at the luminal side of 
intestine such as leptin, angiotensin II and EGF have a mucosal effect on hexose transport 
(14-17). Even though glucose is the main regulator of its own absorption, the modulatory 
effect of gut-derived-molecules on intestinal sugar absorption plays a critical role in the 
adaptation to dietary environment. However, to our knowledge, nothing is known concerning 
the effect of RELM-β on intestinal absorption of glucose. A local action of RELM-express 
in the jejunum is likely even though the highest expression of RELM-is found in colonic 
goblet cells (2). There is also evidence that RELM- expression can be upregulated in rat (18) 
and mice (19) goblet cells of proximal intestine. Considering that RELM-β expression is 
regulated by nutrients/insulin and inflammatory cytokines, it seems important to explore 
whether RELM-β can regulate glucose jejunal absorption. 
 In the present study, we show that exogenous RELM-β acted as a luminal effector in 
enhancing glycemia during OGTT carried out in mice and rats. The use of rat jejunal strips 
mounted in Ussing chamber indicated that RELM-β can directly inhibit SGLT-1 activity 
induced by glucose. The activation of AMPK has been shown to down-regulate SGLT-1 
transport and upregulate glucose uptake by GLUT2 (20). The in vitro and in situ 
experiments performed with rat jejunal segments indicate that RELM-β increases 
transepithelial glucose transport by switching the active transport into passive entry. The 
mechanism involved activation of AMPK and PKC kinases and an insertion of GLUT2 
transporters in jejunal brush border membranes. These data suggest that RELM-β, a gut-
derived hormone, can directly modulate intestinal glucose transport. 
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RESEARCH DESIGN AND METHODS 
Animals. Male Wistar rats weighing 220-240 g and male C57BL/6J mice of 20-25 g weight 
were from Centre Elevage Janvier, Le Genest-St-Isle, France. The animals had free access to 
tap water and standard food and were treated in accordance with European Community 
guidelines concerning care and use of laboratory animals.  
Glucose tolerance test.  Gavages of conscious rats or mice with 1 g of glucose per kg of body 
weight were performed after a 16 h fast using a D-glucose solution without (control) or with 
RELM-  The total bolus volume for mice and rats was 0.25 ml and 1 ml respectively and 
the amount of glucose in each bolus was adjusted for the animal weight. The recombinant 
murine RELM-(18 kDa, PeproTech, Neuilly-sur-Seine, France) used was highly purified by 
high-performance liquid chromatography and was endotoxin-free. RELM- at a final 
concentration of 0.1 and 1 nmol/L, results in dose range of 0.01-0.1 ug per Kg of body 
weight. RELM- is a stable molecule as high amounts of the homodimer form have been 
detected in mice and human stools (21). Before starting the oral glucose tolerance test 
(OGTT), blood samples were taken from the tail and fasting blood glucose levels (mg/dl) 
were determined (ACCU-CHEK; Roche Diagnostic, Meylan, France). The bleeds were 
further taken at 15, 30, 60 and 120 min after oral glucose administration. These experiments 
were performed at least with 6-10 individual animals. 
Tissue preparation and short-circuit measurement. Rats were fasted for 16 h and were 
killed by pentobarbital overdose. The proximal jejunum was dissected out and four adjacent 
samples were mounted in Ussing chambers as described previously (22). The tissues were 
bathed with 4 ml of KRB solution (pH 7.4) with 10 mmol/L glucose at 37°C. In the solution 
bathing the mucosal side of the tissue, glucose was replaced by mannitol. Both solutions 
were gassed with 95% O2/5% CO2. Electrogenic ion transport was monitored continuously 
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as short-circuit current (Isc) by using an automated voltage clamp apparatus (DVC 1000; 
WPI, Aston, England) linked through a MacLab 8 to a MacIntosh computer. KRB alone 
(vehicle) or containing RELM- (0.001-1 nmol/L) was added in the mucosal bath 2 min 
before a glucose challenge. Carbachol (100 mmol/L) was added at the end of each 
experiment as a control. Further, similar tests were performed with RELM- incubated 
overnight at 4°C with a rabbit polyclonal antibody raised against RELM-. Results were 
expressed as the intensity of the Isc (µA/cm
2
) or as the percentage of the peak Isc obtained 
after glucose challenge (measured after 3 min) over basal Isc (measured just before the 
addition of glucose). 
Transmural transport of hexoses. The experiments were performed using jejunal sacs from 
adult Wistar rats.  Animals were fasted for 16 h and were killed by pentobarbital overdose. 
The proximal jejunum was dissected out and rinsed in cold saline solution. Jejunal loops (4 
cm long) were prepared and 0.5 ml of KRB solution without (control) or with 1 nmol/L 
RELM-β was inserted inside the jejunal lumen. The jejunal loops were incubated for 15 min 
in oxygenized KRB at 37°C and conditions were maintained during hexose transport assay. 
The corresponding jejunal loops were filled with 1 ml of KRB solution without (control) or 
with 1 nmol/L RELM-β and containing 0.02 μCi/ml of the isotopic tracer D-[1-14C] glucose 
(49.5 mCi/mmol) and glucose to obtain a final concentration of 10, 30 and 100 mmol/L. 
Similarly, we studied the paracellular transport with 30 mmol/L mannitol and the isotopic 
tracer D-[1-
14C] mannitol (59 mCi/mmol) at 0.2 μCi/ml. All the jejunal loops were incubated 
in 10 ml of KRB solution during the indicated time. The radioactivity was measured in the 
collected samples of serosal KRB solution and used to calculate glucose or mannitol transport 
as pmoles per mg of jejunal protein. Five independent experiments were performed and 
significance is expressed as * p<0.05,** p<0.01. 
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Western blot analysis. Rats were anesthetized by pentobarbital and laparotomized for in 
situ experiments. Three jejunal segments (5 cm long) were tied and filled with 3 ml of KRB 
without (control) or with 1 nmol/L RELM-. After 3 min of in situ incubation, 3 ml of 60 
mmol/L glucose solution were injected in the lumen so as to obtain a final concentration of 
30 mmol/L. After a further 3 min, these loops were removed and opened along the 
mesenteric border and the mucosa was scraped off on ice with a glass blade. Total cell 
protein extracts and BBMs were prepared from the scrapings as previously described (23) 
and enrichment was estimated by determination of alkaline phosphatase activity (20-fold 
increase of activity in BBMs). Solubilised proteins were resolved by electrophoresis on 10 
% SDS-PAGE gels and transferred onto nitrocellulose membranes for immunoblot analysis. 
The following rabbit antibodies were used at a 1:1000 dilution; SGLT-1 (AB 1352; 
Chemicon International, Temecula, CA); GLUT2 , PKC II (sc-9117 , sc-210,  Santa Cruz 
Biotechnology, Tebu-Bio, France); phospho-AMPK- (Thr172) , AMPK- (23A3), 
phospho-PKC (pan  (2531, 2603, 190D10; Cell Signalling Technology, Ozyme, France). 
The intensity of the specific immunoreactive bands was quantified using NIH Image (Scion, 
Frederick, MD).  
Glucose uptake experiments. Uptake experiments were performed using rat intestinal 
everted rings as previously described (24). Briefly, groups of 8 intestinal rings were 
incubated at 37°C for 15 min in oxygenized KRB buffer in the absence (control) and the 
presence of RELM-(1 nmol/L) and cytochalasin B as indicated. Then the rings were 
incubated for 2 min in an uptake solution corresponding to a KRB buffer containing 30 
mmol/L glucose and 0.1 µCi/ml of the isotopic tracer D-[1-
14
C] glucose. After adding the 
uptake solution, the rings were washed in ice-cold KRB solution and radioactivity 
incorporated in the tissue was quantified by liquid scintillation. Data were not corrected for 
extracellular substrate since RELM- was found not to affect paracellular diffusion as 
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shown in Fig. 3A. Total protein from homogenized tissue with a Dounce homogenizer was 
determined with BCA reagent from Pierce (Thermo Scientific, Brebières, France). Results 
are expressed as µmol glucose/g tissue protein. 
Chemicals. Recombinant murine RELM- was purchased from PeproTech (Neuilly-sur-
Seine, France). Antibody raised against RELM- was a gift from Dr. Blagoy Blagoev 
(University of Southern Denmark). D-[1-14C] Mannitol, GE Healthcare Amersham 
Biosciences, (les Ulis, France) and D-[1-14C] glucose, Perkin Elmer, (Boston USA), 
compound C from Merck Sharp & Dohme-Chibret (Paris, France). All other chemical 
reagents were purchased from Sigma (St. Louis, MO). 
Statistical analysis. All results were expressed as means ± SE. One-way ANOVA with 
Turkey-Kramer multiple comparisons posthoc-test was performed using GraphPad Prism 
version 4.0 for Windows (GraphPad Software, San Diego, CA). The level of significance 
was set at p<0.05.  
RESULTS 
Effect of RELM- on glucose tolerance tests. Oral administration of RELM- increased 
glycemia during oral glucose tolerance test carried out in mice (Fig. 1A) and rats (Fig. 1B) 
as compared with control groups. The area under the curve was significantly (p<0.05) 
increased in mice when RELM- was used at 1 nmol/L and the two doses used (0.1 and 1 
nmol/L) were effective in rats (insets, Fig. 1A and B). A similar 15% increase in blood 
glucose as compared to control was observed in both mice and rats. These data show that 
luminal administration of exogenous RELM- is active in vivo as previously described (6). 
Mucosal RELM- inhibits Na+-dependent glucose transport. The route of glucose entry 
can involve active Na
+
-dependent glucose transporter (SGLT-1) or diffusive transporter 
GLUT2. We used the Ussing chamber to characterize the effect of mucosal RELM- on rat 
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intestinal active glucose transport (SGLT-1). Rat jejunal mucosa mounted in the chamber was 
allowed to reach a steady state (usually 40 min). Addition of 10 mmol/L glucose in the 
mucosal bath induced a rise in Isc (maximum after 3 min) representing an increase in SGLT-1 
activity. Addition of RELM- to the mucosal side 2 min before glucose challenge induced a 
marked and dose-dependent inhibition of glucose-induced Isc. As shown in Fig. 2A, addition 
of RELM- to the mucosal side inhibited glucose transport by jejunal mucosa in a 
concentration-dependent manner. Maximal inhibition was achieved with 0.1 nmol/L RELM-
. The concentration that produced a half-maximal inhibition (IC50) of glucose transport was 
3 pmol/L. Further, an overnight incubation of 0.1 nmol/L RELM- with an antibody raised 
against RELM- countered the inhibition of glucose-induced Isc by RELM- as shown in 
Fig. 2B. We next investigated if the observed inhibition by RELM- was associated with an 
altered abundance of SGLT-1 in jejunal brush border membranes (BBMs). A typical 
immunoblot of SGLT-1 protein in BBMs after glucose challenge in the presence or the 
absence of RELM- is shown in Fig. 2C.  The mean densitometry of three separate blots 
shows that glucose increased the amount of SGLT-1 protein in BBMs by 1.5-fold as 
compared to control. This increase is reduced by half in the presence of RELM- 
RELM- modulates jejunal glucose transport. We isolated rat jejunum and performed in 
vitro studies of transmural glucose transport to directly evaluate the effect of RELM- on 
intestinal transport. As shown in Fig. 3A, luminal glucose in jejunal loops significantly 
increased net mucosal to serosal glucose flux. A dose-dependent effect on glucose transport 
was observed with increasing glucose concentrations 10, 30 and 100 mmol/L. Further, 
RELM-, at 1 nmol/L, significantly enhanced the jejunal transport of 10, 30 and 100 
mmol/L glucose but not that of 30 mmol/L mannitol. Thus, increased jejunal glucose 
transport induced by RELM- is unlikely to have been caused by changes in paracellular 
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permeability. This is in line with histological studies of the jejunum tissues used in these 
experiments which did not show any visible mucosal deterioration (data not shown). 
Further, experiments were performed to identify if the effect of RELM- implicated 
potential downstream kinases, PKC and AMPK, which are  known as key effectors of 
intestinal glucose transport (6, 20, 23, 25). The AMPK inhibitor, compound C, and the PKC 
inhibitor, chelerythrine, inhibited the 30 mmol/L glucose-induced jejunal glucose transport 
as shown respectively in Fig. 3B and 3C. The insets represent the area under the curve of the 
30 min glucose transport kinetics. RELM- significantly increased glucose transport by 
approximately 2-fold and this effect was blunted by compound C and chelerythrine as 
shown respectively in Fig. 3B and 3C. These results indicate a likely involvement of PKC 
and AMPK in the luminal effect of RELM- on glucose uptake. 
RELM- stimulates phosphorylation of AMPK and translocation of PKC II.  The 
above results prompted us to assess by in situ experiments the cellular effects of RELM- 
on AMPK and PKC. Jejunal segments were injected with a KRB solution alone or 
containing 30 mmol/L glucose in the absence and the presence of 1 nmol/L RELM- The 
mucosal scrapings of jejunum were examined by Western blot analysis. The results 
indicated that glucose as well as RELM- stimulated AMPK phosphorylation over control 
values as shown in Fig. 4A. The corresponding mean densitometric analysis indicates that 
RELM- induced a 3-fold increase in AMPK phosphorylation. A further increase in the 
phosphorylation of AMPK occurred when glucose and RELM- were added together.  
Similarly, RELM- induced a 3-fold increase in PKC phosphorylation in line with our data 
(6) in the mouse colon (data not shown). This prompted us to study the translocation of 
cytosolic PKC II of enterocytes to BBMs, a mechanism which is associated with intestinal 
glucose transport (20, 23). We performed Western blot analysis to determine the expression 
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of PKC II in BBMs obtained from intestinal segments which were incubated with glucose 
(30 mmol/L) or RELM- (1 nmol/L) as described above. As shown in Fig. 4B, RELM- or 
glucose induced respectively 1.5 or 2-fold increase of PKC II at the BBMs as compared to 
control values. A further increase (2.7-fold compared to the control) of PKC II at the 
BBMs was observed when RELM- and glucose were added together. These results suggest 
that RELM- stimulates the phosphorylation of AMPK and PKC as well as an increased 
shift of PKC II to the BBMs of rat jejunal tissue. 
RELM- increases GLUT2 activity and its expression at BBMs.  
We explored whether RELM- could enhance the glucose-induced GLUT2 translocation to 
the apical membrane of enterocytes. To this end, we measured glucose uptake in rat everted 
jejunal rings in the presence of RELM- and without or with cytochalasin B, a competitive 
inhibitor of GLUT2 (26). As shown in Fig. 5A, cytochalasin B inhibited glucose uptake by 
50 % in agreement with the implication of GLUT2 in glucose uptake (27, 28). RELM- 
enhanced glucose uptake by 2-fold and this effect was also strongly inhibited by 
cytochalasin B. Further, we performed Western blot analysis to determine the expression of 
GLUT2 in BBMs obtained from intestinal segments that had been incubated with RELM- 
under the same conditions as above. We observed that glucose or RELM-alone induced 
respectively a 4- or 3-fold increase in the amount of GLUT2 found in the brush-border 
fraction respectively (Fig. 5B). When glucose and RELM- were added together, a further 
increase in the amount of GLUT2 was observed (5-fold as compared to control). This 
suggests that RELM- enhanced glucose uptake is due to an increased insertion of GLUT2 
into the BBMs. 
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DISCUSSION  
In the present study, we show that RELM-, a resistin-like molecule, can directly 
increase jejunal absorption of glucose in the rat. Several lines of evidence suggest that trans-
epithelial transport of glucose in the small intestine can be mediated by an active absorption 
through Na
+
/glucose cotransporter (SGLT-1) as well as  by a diffusive component GLUT2 
at the apical membrane (27). We found that RELM- inhibited the activity of SGLT-1 while 
enhancing the presence of GLUT2 at the brush border membrane of enterocytes. Morever, 
the increased jejunal glucose transport induced by RELM- was inhibited by cytochalasin B 
in agreement with a functional role of GLUT2. The underlying molecular mechanism 
involves the activation of PKC II and AMPK kinases as described for such reciprocal 
regulation of glucose transporters (20).  
The acute treatment of rat jejunum with RELM- had no significant effect on passive 
mannitol movement suggesting that RELM- increases glucose transport by the use of 
transporters. We found that mucosal RELM- inhibited the activity and the translocation of 
cytosolic SGLT-1 to cell membranes. This effect was blunted by an antibody raised against 
RELM-. Other peptides such as leptin, angiotensin II and CCK-8 have also been shown to 
inhibit SGLT-1 activity (14, 16, 28). We show that in contrast to CKK-8 which seems to 
have no effect on GLUT2 (28), RELM- can induce GLUT2 translocation. Indeed, in 
response to RELM- the amount of GLUT2 was increased in the BBMs. Similarly, a rapid 
insertion of GLUT2 to apical membrane in response to another gut-peptide, GLP-2, has 
been reported (29, 30). Taken together, these findings suggest the involvement of GLUT2 in 
RELM- stimulated glucose uptake.  
  The mechanisms responsible for RELM- effect may involve the activation of PKC (6) 
and AMPK (25) which have been shown to regulate jejunal glucose transporters (20). This is 
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sustained by the report that luminal EGF increases jejunal glucose transport in rabbit through 
PKC activity (31). We found that chelerythrine, an inhibitor of PKC, blocked RELM- 
stimulation of glucose uptake. The effect of RELM- is accompanied by an increase in the 
amount of PKC II at the BBMs. The activation of PKC has been shown to inhibit SGLT-1 
mediated transport of hexoses (14, 32). In oocytes expressing rat and rabbit SGLT-1, the 
activation of PKC decreases the maximum rate of transport for both isoforms. This change is 
accompanied by proportional change in the number of SGLT-1 molecules at the plasma 
membrane, indicating that PKC regulates endocytosis of the vesicles containing the 
transporter (33). Further, SGLT-1 contains a consensus site of PKC phosphorylation and thus 
PKC phosphorylation of the transporter could control its activity (34). These data are in line 
with our results showing that RELM- inhibits SGLT-1 activity and its translocation to 
BBMs in rat small intestine.  
 The activation of AMPK has been shown to downregulate SGLT-1-dependent glucose 
transport but also to enhance GLUT2 translocation to the apical membrane of  the jejunum 
(20). This  effect of AMPK leads to an increased glucose uptake in jejunum (20) as well as in 
muscle (35). Interestingly, several hormones have been shown to regulate AMPK in a strictly 
tissue-specific manner (36). We demonstrate that the compound C blocked RELM- 
stimulation of glucose transport in rat intestine suggesting the involvement of AMPK. 
Humans and rodents express two isoforms of the catalytic subunit (1, 2) which form the 
heterotrimeric complex AMPK (,  and ) known to serve as a regulator of energy balance 
(37). We showed that RELM- can increase the phosphorylation of the conserved threonine 
residue (Thr-172) of 1 in the jejunal mucosa which is crucial for the AMPK activity. As 
evoked above, activated PKC decreases the number of SGLT-1 transporters but can also 
activate the translocation of GLUT2 to BBMs as described elsewhere (23). Thus luminal 
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RELM- can directly enhance glucose transport by mustering GLUT2 at BBMs through PKC 
and AMPK activation. 
 This inverse regulation of SGLT-1 and GLUT2 by luminal RELM- may be important 
when enterocytes require energy as shown in stress-induced pathology (38). The energy 
sensor molecule AMPK as well as PKC can increase the GLUT2 energy-independent 
pathway to override that of SGLT-1 which requires energy (20, 32). In agreement with this 
concept, the SGLT-1-mediated absorption of nutrients such as galactose and glucose is 
decreased during either systemic (39) or intestinal inflammation (40). Further, to meet the 
increased metabolic demand of inflamed tissue, it has been shown that pro-inflammatory 
cytokines (IL-8, IL-6 and IL-1) can increase jejunal absorption of glucose without changes in 
BBM SGLT-1 content (41). An increased expression of RELM- has been described in the 
intestine during jejunal inflammation (19, 42 43). The expression of RELM- is increased by 
several pro-inflammatory cytokines and by LPS (9, 21) and they may act together to modulate 
intestinal glucose absorption. Thus, the enhanced glucose absorption by RELM- in response 
to inflammatory stimulus may contribute to the associated energy demand.  
 Obese and insulin-resistant rodent models which are characterized by a low grade 
inflammation are also associated with an increased expression of the gut-derived RELM-
). Expression of RELM-has been shown in mice (18) and rat (19) proximal intestine 
and the peptide may act locally in a paracrine manner or as a circulating hormone linking the 
gut to the liver. When given by gavage, it is possible that RELM- could be partly absorbed 
by the small intestine to reach the blood as demonstrated for leptin (44). In favour of a 
hormonal effect, the infusion of intestinal RELM- in mice has been shown to promote a 
marked increase in the rate of hepatic glucose production (7). This was associated with a 
rapidly induced hepatic but not peripheral insulin resistance. We observed that acute RELM- 
administration in the intestinal lumen of rodents resulted in an increased glycemia in OGTT. 
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This could result from the observed increased intestinal glucose absorption and an acute 
hepatic insulin resistance (7). This is in line with a local intestinal and distant action of this 
gut peptide. As to whether RELM- may also counteract the described insulin inhibition of 
intestinal sugar absorption remains to be established (45). There may be different RELM-
thresholds in insulin target tissues as described for resistin (46). A better understanding of 
RELM- action on different tissues could emerge if putative RELM-receptors were 
identified. In this context, the effect of RELM- may even involve rapid neuronal activation 
since RELM family members RELM- and RELM-can bind to neurons. Other than 
short-regulation, RELM- can have a chronic effect as shown in diet-induced metabolic 
disorders (25). Transgenic mice over-expressing circulating RELM- exhibited significant 
hyperglycemia, hyperlipedemia when fed on high fat diet. In conclusion, our study shows that 
RELM- increases intestinal glucose transport. Further studies may reveal if this process in 
conjunction with an adverse nutritional and inflammatory status, can participate in the onset 
of diabetes.  
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FIGURE LEGENDS 
FIG. 1: Oral glucose tolerance tests (OGTT) in mice and rats. OGTT (1g/kg) were performed 
in overnight-fasted mice (A) or rats (B) with a 15% D-glucose solution without (, dotted lines) 
or with RELM-(0.1 nmol/L,  and 1 nmol/L, ). Glucose concentration was determined in 
blood samples from the tail and are expressed as mg/dl over the time points (minutes). Each 
point is the mean + SE; n= 6-10. *p <0.05 versus control. Area under the curve (inset) is 
expressed in arbitrary units (AU). In absence (0, clear bar) and in presence of 0.1 nmol/L (black) 
and 1 nmol/L (hatch) RELM- 
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FIG. 2: Effect of luminal RELM- on glucose-induced Isc. Rat jejunal mucosa was mounted 
in Ussing chamber and the increase in Isc was studied at steady state. Electrogenic (Na
+
) 
transport was followed as an index of the active glucose transport by cotransporter SGLT-1. 
RELM- was added in the mucosal bath 2 min before challenging the tissues with 10 mmol/L 
glucose. Values for Isc were standardized to control values and expressed as percentage of 
controls. A dose-dependent inhibition is shown in (A). The effect of 0.1 nmol/L RELM-after 
an overnight incubation with an antibody against RELM- is shown in (B). Brush border 
membranes (BBMs) were prepared from rat jejunum loops incubated in situ with and without 
luminal RELM- during 6 min. A representative SGLT-1 immunoblot of solubilized BBMs is 
shown in (C). Densitometric analysis of immunoreactive bands was performed using NIH Image 
analysis program. The densitometry represents the amount of SGLT-1 relative to -actin and is 
representative of at least three separate experiments. Each point of the Isc study represents the 
mean ± SE of four to eight noncumulative values from five separate experiments. Significant 
differences from control (*p <0.05 and **p <0.01).  
FIG. 3: Effect of luminal RELM-on transmural transport of hexoses in rat jejunal loops. 
Transmural transport of glucose or mannitol was performed in jejunal sacs from adult Wistar 
rats. In (A), intestinal sacs were incubated at 37°C during 15 min with 1 nmol/L RELM- () or 
vehicle () in oxygenized KRB buffer with glucose at 10, 30 and 100 mmol/L and the isotopic 
tracer D-[1-
14
C] glucose. The radioactivity measured in the collected samples was used to 
calculate glucose transport as pmoles per mg of jejunal protein per min. Results from a similar 
experiment using mannitol (30 mmol/L) are shown in (A). The kinetics of glucose (30 mmol/L) 
transmural transport is shown in the absence (, dotted line) and in the presence of 1 nmol/L 
RELM- () in B and C. In figure B, the AMPK inhibitor (compound C or CC) was incubated 
without () or with RELM- (). Similarly in (C), the PKC inhibitor (chelerythrine chloride or 
CCL) is incubated without () and with RELM-(). The insets show the corresponding area 
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under the curve. The data are representative of the mean + SE of at least 4 individual 
experiments (*p <0.05 and **p <0.01 versus control). 
FIG. 4: RELM- induces phosphorylation of AMPK and translocation of PKC II. Rats 
were anesthetized and their jejunal loops were used for in situ experiments. The loops were filled 
with KRB-buffer with or without 1 nmol/L RELM-. After 3 min, glucose (30 mmol/L) was 
added in this mucosal bath. After a further 3 min, loops were excised and kept on ice before 
scraping off the mucosa. Total protein extraction and BBMs preparation were performed 
immediately as described in Methods. Representative immunoblots for phospho-AMPK (A) in 
mucosal extracts and PKC II (B) in BBMs are shown. The densitometry in A represents the 
amount of phosphorylated kinases relative to total AMPK. The amount of PKC II in BBMs in 
B is relative to total PKC. The data are representative of three separate experiments. 
*Significantly different from control (p <0.05). 
FIG. 5: Effect of RELM- on glucose uptake and GLUT2 trafficking in BBMs. In (A), rat 
jejunal everted rings were incubated in oxygenized KRB-buffer without (control) or with 1 
nmol/L RELM-. The presence of cytochalasin B is indicated. Then, the rings were incubated 
for 2 min in a KRB buffer containing 30 mmol/L glucose and 0.1 µCi/ml of the isotopic tracer 
D-[1-
14
C] glucose). The radioactivity incorporated in the tissue was determined by liquid 
scintillation. The amount of glucose incorporated is expressed as µmol per g of tissue protein. In 
panel (B), rat jejunal loops were treated 6 min with a mucosal bath containing 30 mmol/L 
glucose with or without 1 nmol/L RELM- and BBMs were prepared as described in Methods. A 
representative Western blot analysis of the corresponding protein lysates with GLUT2 antibody 
is shown. Densitometric analysis of immunoblots indicates an increase of GLUT2 in the 
presence of glucose or RELM-. The data are expressed relative to -actin and is representative 
of at least three separate experiments, *Significantly different from control (p <0.05). 
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